Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.9
Journals
TropicalMed
Special Issues
Advances in Drug Treatment for Leishmaniasis
share announcement

Advances in Drug Treatment for Leishmaniasis

A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366). This special issue belongs to the section "Neglected and Emerging Tropical Diseases".

Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 5007

Special Issue Editor

Dr. Juliana Carnielli

E-Mail Website
Guest Editor
York Biomedical Research Institute, Department of Biology, University of York, York YO10 5DD, UK
Interests: Leishmania; Kinetoplastids; drug discovery; target identification; drug resistance; protein kinases

Special Issue Information

Dear Colleagues,

Globally distributed and closely related to poverty, the leishmaniases are neglected tropical diseases, with more than 1 billion people at risk of infection. Leishmaniasis is a vector-borne disease caused by protozoan parasites of the Leishmania genus, which is transmitted by the bite of infectious female sand flies. Cutaneous, mucocutaneous, and visceral leishmaniasis are the three main forms of a complex of leishmaniasis diseases. Visceral leishmaniasis, the most severe form of the disease, is usually fatal if untreated. Given the difficulties associated with vector control and the absence of an effective vaccine, leishmaniasis control relies primarily on chemotherapy. Nevertheless, current therapies have severe shortcomings, highlighting an urgent need for innovative safe and efficacious treatments, understanding the mechanism of resistance to preserve the current available drugs, and the development of innovative approaches for disease control.

This Special Issue of Tropical Medicine and Infectious Diseases aims to gather relevant manuscripts, from basic to translational studies, to cover different aspects of the recent advances in drug treatment for leishmaniasis. For this research topic, we are inviting interested researchers and public health experts to share their relevant findings, either in the form of original research or review papers, focusing on, but not limited to, the following areas: current chemotherapy and recent advances in drug treatment for leishmaniasis (cutaneous, mucocutaneous, visceral leishmaniosis and post-kala-azar dermal leishmaniasis); drug combination; immunotherapy; drug-delivery systems for the treatment of leishmaniasis; target identification and validation in Leishmania; drug development for leishmaniasis; drug resistance to leishmaniasis; mechanisms of drug action and drug resistance; prognostic markers for leishmaniasis treatment; and diagnosis.

Dr. Juliana Carnielli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • visceral leishmaniasis
  • cutaneous leishmaniasis
  • mucosal leishmaniasis
  • drug discovery
  • target identification
  • drug combination
  • immunotherapy
  • drug resistance
  • prognostic markers
  • diagnosis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

13 pages, 1139 KiB  
Article
Hematological and Clinical Features Associated with Initial Poor Treatment Outcomes in Visceral Leishmaniasis Patients with and without HIV Coinfection in Gondar, Northwest Ethiopia
by Muluneh Ademe, Yaneth Osorio, Rawliegh Howe, Saba Atnafu, Tadele Mulaw, Helina Fikre, Bruno L. Travi, Asrat Hailu, Peter C. Melby and Tamrat Abebe
Trop. Med. Infect. Dis. 2023, 8(1), 36; https://doi.org/10.3390/tropicalmed8010036 - 04 Jan 2023
Viewed by 2518
Abstract
Ethiopia is among the countries with a high leishmaniasis burden. In this retrospective review, we aimed to determine hematological and clinical features associated with initial poor treatment outcomes of visceral leishmaniasis (VL) patients. The majority of VL cases in this study had leucopenia [...] Read more.
Ethiopia is among the countries with a high leishmaniasis burden. In this retrospective review, we aimed to determine hematological and clinical features associated with initial poor treatment outcomes of visceral leishmaniasis (VL) patients. The majority of VL cases in this study had leucopenia (94.3%), thrombocytopenia (87.1%), and anemia (85.9%). HIV coinfection was present in 7.0% (n = 23) of VL cases. At the center, VL patients without HIV coinfection were treated with sodium stibogluconate and paromomycin combination, whereas HIV coinfected cases were treated with AmBisome and miltefosine combination therapy. End-of-treatment cure rates among HIV-positive and HIV-negative visceral leishmaniasis cases, respectively, were 52.2% and 96.9%. Case fatality rates were 34.8% and 2.7% in HIV-positive and HIV-negative cases, respectively. Overall, non-survivors in this study were more likely to have HIV (55.0% vs. 4.1%, p < 0.001), sepsis (15.0% vs. 1.4%, p = 0.019), and dyspnea (40.0% vs. 2.7%, p < 0.001) at admission. In this regard, particular attention to the management of superimposed disease conditions at admission, including sepsis, HIV, and dyspnea, is needed to improve VL patients’ treatment outcomes. The inadequacy of the current treatments, i.e., AmBisome and miltefosine combination therapy, for HIV coinfected visceral leishmaniasis patients requires further attention as it calls for new treatment modalities. Full article
(This article belongs to the Special Issue Advances in Drug Treatment for Leishmaniasis)
►▼ Show Figures

Figure 1

Other

Jump to: Research

9 pages, 4215 KiB  
Case Report
Impetiginous Cutaneous Leishmaniasis after COVID-19 Infection in a Patient with Poor Cardiac Profile: A Case Report and Literature Review
by Hend Alotaibi, Abdulelah Aldossari and Sultan Alnasser
Trop. Med. Infect. Dis. 2023, 8(9), 443; https://doi.org/10.3390/tropicalmed8090443 - 10 Sep 2023
Viewed by 1528
Abstract
Cutaneous leishmaniasis incidence has been rising in the past couple of decades. Standard therapy often includes antileishmanial drugs; however, due to their low safety and toxicity threshold, alternative treatments are being investigated. The association between COVID-19 and cutaneous leishmaniasis remains unclear and exploring [...] Read more.
Cutaneous leishmaniasis incidence has been rising in the past couple of decades. Standard therapy often includes antileishmanial drugs; however, due to their low safety and toxicity threshold, alternative treatments are being investigated. The association between COVID-19 and cutaneous leishmaniasis remains unclear and exploring this connection may offer crucial insights into the pathophysiology of and treatment strategies for infected patients. In this article, we describe a case of a male patient with a history of cardiac and other comorbidities who presented with cutaneous leishmaniasis in the form of impetigo-like skin lesions after being infected with COVID-19. Due to the patient’s poor cardiac profile, sodium stibogluconate was not used and an alternative therapeutic approach was employed. The patient was treated with oral terbinafine, cryotherapy on specific lesions, and a course of cephalexin. Following the course of treatment and subsequent follow-up, the patient exhibited complete resolution and healing of the lesions with scarring, and no active lesions or recurrence were observed. This case highlights the potential for alternative treatment strategies for cutaneous leishmaniasis in patients with comorbidities and emphasizes the importance of further research to better understand the link between COVID-19 and cutaneous leishmaniasis. Full article
(This article belongs to the Special Issue Advances in Drug Treatment for Leishmaniasis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop